Omnicell, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2021
November 02, 2021 at 07:30 am EDT
Share
Omnicell, Inc. provided earnings guidance for the fourth quarter and full year 2021. For the quarter, the company expects total GAAP and non-GAAP revenues to be between $308 million and $313 million
For the year, the company expects total GAAP and non-GAAP revenues to be between $1.129 billion and $1.134 billion. Company expects product bookings to be between $1.130 billion and $1.170 billion.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
OMNICELL, INC. 
